{"id":701662,"date":"2022-10-27T07:54:06","date_gmt":"2022-10-27T11:54:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/"},"modified":"2022-10-27T07:54:06","modified_gmt":"2022-10-27T11:54:06","slug":"foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/","title":{"rendered":"Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Oct.  27, 2022  (GLOBE NEWSWIRE) &#8212; Foghorn<sup>\u00ae<\/sup> Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Thomas Lynch Jr., M.D., to its Board of Directors.<\/p>\n<p>Dr. Thomas J. Lynch, Jr. is president and director of Fred Hutchinson Cancer Center and holder of the Raisbeck Endowed Chair, and sets the strategic direction of the center, oversees center-wide initiatives, and represents the Fred Hutch\u2019s interests to major partners and governmental bodies. Prior to his role at Fred Hutch, Dr. Lynch served as Chief Scientific Officer at Bristol-Myers Squibb. Prior to that he held several leadership and clinician roles as director of Yale Cancer Center, physician in chief at Smilow Cancer Hospital, and chief of hematology-oncology at Massachusetts General Hospital.<\/p>\n<p align=\"justify\">\u201cTom is a world-renowned scientist and oncologist. I am delighted to have Tom joining our board of directors at this important time in the company\u2019s evolution as we continue to advance both FHD-609 and FHD-286 through clinical trials and progress other pipeline programs towards the clinic,\u201d said Foghorn CEO Adrian Gottschalk. \u201cTom\u2019s deep scientific knowledge and clinical experience will be invaluable in helping to guide the Company through its next stage of growth.\u201d<\/p>\n<p>Douglas Cole, M.D., Flagship Pioneering Managing Partner, Foghorn Co-Founder and Chairman of the Board, continued, \u201cWe are thrilled to welcome Tom to the Foghorn Board. He is widely recognized for his dedication to improving patients\u2019 lives through his work as a clinician and academic and industry leader. He understands patients\u2019 needs, the research enterprise, and drug development. Tom\u2019s experiences and perspectives will contribute critical insights to Foghorn\u2019s mission to help people with cancer and other serious diseases.\u201d<\/p>\n<p align=\"justify\">\u201cI am excited to be joining the board of\u00a0Foghorn and I look forward to collaborating with the other board members and the Foghorn team during this important stage of Foghorn\u2019s journey,\u201d said\u00a0Dr. Lynch.<\/p>\n<p align=\"justify\">\n        <strong>About Foghorn Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Foghorn<sup>\u00ae<\/sup>\u00a0Therapeutics Inc. is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control<sup>\u00ae<\/sup>\u00a0platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yofeNz_2ytlp8q36UXUxpnIKu_n6v7zcpjvwp8fUIAm4KusO_JoByxpMHOnlT_Z7MVDa9QCcP0GdlejBin6B6Q==\" rel=\"nofollow noopener\" target=\"_blank\">www.foghorntx.com<\/a> for more information on the company, and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3ZfmfNI-Cm-OMSLG4zdQB3tAYUyD-MjHWqe45NM5uQmCz9CaWv37hyLUzqsHX0s3v5HaWGVD30sLk8_apzbAgdmiYdUzC4tjSLgs5OZEiNM=\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mHPrRbmpguGCit2FW9PXqBFCt4f7DBoBePvqQI5r_kKzJkOef9YC99W1nHWCGGjhqs9y079oGKyV2wqlw5prRa9RzMfxtPmg-VuKyuXT9nohSmJzQ7AetgP6njda5X8q\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d regarding the Company\u2019s growth and its goal of becoming a fully-integrated biotech company. Forward-looking statements include statements regarding the Company\u2019s clinical trials, product candidates and research efforts and other statements identified by words such as \u201ccould,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201clikely,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cseeks,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201ccontinues,\u201d \u201cprojects\u201d and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MU2ODL3BHhByVSicsmzFA6X80CCUuv4b8_FvajQPl4qgW52OczIux3VBwPE4X9d-_g-DUqB9rl0v8mB6WRq0Ib7P7wdSPhV1kiQvVD2oSw0=\" rel=\"nofollow noopener\" target=\"_blank\">bstrain@foghorntx.com<\/a><\/p>\n<p>Karin Hellsvik, Foghorn Therapeutics Inc. (Media)<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vlxtj6EOIN19lEmZ94WR7a_P1opHCaOVpqng6yk9Cg-5EdlHi9JxSyaZ7WOAL5UqSvevbOMsLvO08vM-GYytyuVdp0ZoNoqi_siHhDVjga8=\" rel=\"nofollow noopener\" target=\"_blank\">khellsvik@foghorntx.com<\/a><\/p>\n<p>Michael Lampe, ScientPR (Media)<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hPTgMlXId0ByOBU_Ch48BYZy_mZzhMyhpNNZ-Gw3Wd7Ksv5ebN5PtK8U8TBW7mS2XTXHxqETAUN0fjR8VZKhq-ddYWmBJtOCoM1FH5uZcx0=\" rel=\"nofollow noopener\" target=\"_blank\">michael@scientpr.com<\/a><\/p>\n<p>Hans Vitzthum, LifeSci Advisors (Investors)<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=viHmdwFgboq0LlaF4Jgm-IFhtBihleC18uj-hJ-jXzWRyxiTs2XhLEh8tU4BFe8jXU7vKpfGq-bMQnalYtoqSz4rvZIJD9g37d5zteM_Ly8=\" rel=\"nofollow noopener\" target=\"_blank\">hans@lifesciadvisors.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzA4NSM1MjI2NDY3IzIyMDI4NjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OWZkODA3MWMtYTE2ZS00MGU5LTgwMGUtZTQyODA0NDEyZWNkLTEyMTQ0MTU=\/tiny\/Foghorn-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Thomas Lynch Jr., M.D., to its Board of Directors. Dr. Thomas J. Lynch, Jr. is president and director of Fred Hutchinson Cancer Center and holder of the Raisbeck Endowed Chair, and sets the strategic direction of the center, oversees center-wide initiatives, and represents the Fred Hutch\u2019s interests to major partners and governmental bodies. Prior to his role at Fred Hutch, Dr. Lynch served as Chief Scientific Officer at Bristol-Myers Squibb. Prior to that he held several leadership and clinician roles as director &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-701662","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Thomas Lynch Jr., M.D., to its Board of Directors. Dr. Thomas J. Lynch, Jr. is president and director of Fred Hutchinson Cancer Center and holder of the Raisbeck Endowed Chair, and sets the strategic direction of the center, oversees center-wide initiatives, and represents the Fred Hutch\u2019s interests to major partners and governmental bodies. Prior to his role at Fred Hutch, Dr. Lynch served as Chief Scientific Officer at Bristol-Myers Squibb. Prior to that he held several leadership and clinician roles as director &hellip; Continue reading &quot;Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T11:54:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzA4NSM1MjI2NDY3IzIyMDI4NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors\",\"datePublished\":\"2022-10-27T11:54:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/\"},\"wordCount\":677,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzA4NSM1MjI2NDY3IzIyMDI4NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/\",\"name\":\"Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzA4NSM1MjI2NDY3IzIyMDI4NjI=\",\"datePublished\":\"2022-10-27T11:54:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzA4NSM1MjI2NDY3IzIyMDI4NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzA4NSM1MjI2NDY3IzIyMDI4NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Thomas Lynch Jr., M.D., to its Board of Directors. Dr. Thomas J. Lynch, Jr. is president and director of Fred Hutchinson Cancer Center and holder of the Raisbeck Endowed Chair, and sets the strategic direction of the center, oversees center-wide initiatives, and represents the Fred Hutch\u2019s interests to major partners and governmental bodies. Prior to his role at Fred Hutch, Dr. Lynch served as Chief Scientific Officer at Bristol-Myers Squibb. Prior to that he held several leadership and clinician roles as director &hellip; Continue reading \"Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-27T11:54:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzA4NSM1MjI2NDY3IzIyMDI4NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors","datePublished":"2022-10-27T11:54:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/"},"wordCount":677,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzA4NSM1MjI2NDY3IzIyMDI4NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/","name":"Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzA4NSM1MjI2NDY3IzIyMDI4NjI=","datePublished":"2022-10-27T11:54:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzA4NSM1MjI2NDY3IzIyMDI4NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzA4NSM1MjI2NDY3IzIyMDI4NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-dr-thomas-j-lynch-jr-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=701662"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701662\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=701662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=701662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=701662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}